Physician profile
Borislav Mravkov
NPI 1376680660
$936.55
in general payments reported to CMS, 2019-2025
21 companies · $42.95 in 2025
The $42.95 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.89 · 2022: $487 · 2023: $161 · 2024: $234 · 2025: $42.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $438.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $250.94 | 2022-2025 | |
| Biogen, INC. | $134.11 | 2022-2024 | Vumerity, Tysabri |
| Alexion Pharmaceuticals, INC. | $94.42 | 2022 | |
| Kyowa Kirin, INC. | $57.78 | 2022-2024 | Nourianz |
| Lundbeck LLC | $54.72 | 2022-2023 | Vyepti |
| Abbvie INC. | $47.88 | 2022-2023 | |
| Ge Healthcare | $36.92 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $29.55 | 2022-2023 | Ingrezza, Ongentys |
| Banner Life Sciences, LLC | $24.36 | 2022 | |
| Impel Pharmaceuticals INC. | $24.31 | 2022 | |
| Argenx US, INC. | $23.74 | 2022 | |
| Tg Therapeutics, INC. | $21.82 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.09 | 2022 | |
| Lilly USA, LLC | $16.32 | 2024 | Amyvid |
| Genentech USA, INC. | $16.10 | 2024 | Ocrevus |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $15.70 | 2022 | |
| Tanabe Pharma America, INC. | $15.60 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.34 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.43 | 2022 | |
| Neurelis, INC. | $12.53 | 2022 | |
| Livanova USA, INC. | $11.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Borislav Mravkov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.